The BRD4 inhibitor (JQ1) competes with BRD4 for binding to acetylated lysines, displacing BRD4 from super-enhancers within the MYC oncogene and reducing MYC expression, resulting in anti-cancer effects in hematopoietic cancers, PDAC and MYCN-driven cancers [144,145]. Here, MYCN is linked to cancer.